• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by MoonLake Immunotherapeutics

    7/3/25 1:23:21 PM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MLTX alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001772130
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    MoonLake Immunotherapeutics
    SEC File Number
    001-39630
    Address of Issuer
    DORFSTRASSE 29
    ZUG
    SWITZERLAND
    6300
    Phone
    41 41 510 8022
    Name of Person for Whose Account the Securities are To Be Sold
    Moukheibir Catherine
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Class A
    Fidelity Brokerage Services LLC
    900 Salem Street
    Smithfield � RI � 02917
    235001146594.656347425307/03/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Class A07/03/2025Option Granted - 04/06/2022IssuerCheckbox not checked2350007/03/2025Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    07/03/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Daniel Tucci, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Catherine Moukheibir

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $MLTX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MLTX

    DatePrice TargetRatingAnalyst
    5/19/2025$61.00Peer Perform → Outperform
    Wolfe Research
    3/18/2025$67.00Outperform
    RBC Capital Mkts
    1/17/2025$62.00 → $82.00Neutral → Buy
    Goldman
    11/5/2024$92.00 → $73.00Outperform
    Wedbush
    8/26/2024Outperform → Peer Perform
    Wolfe Research
    6/25/2024$104.00Outperform
    Oppenheimer
    4/2/2024$62.00Neutral
    Goldman
    2/15/2024$77.00Outperform
    Wolfe Research
    More analyst ratings

    $MLTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • MoonLake Immunotherapeutics upgraded by Wolfe Research with a new price target

      Wolfe Research upgraded MoonLake Immunotherapeutics from Peer Perform to Outperform and set a new price target of $61.00

      5/19/25 8:47:20 AM ET
      $MLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital Mkts initiated coverage on MoonLake Immunotherapeutics with a new price target

      RBC Capital Mkts initiated coverage of MoonLake Immunotherapeutics with a rating of Outperform and set a new price target of $67.00

      3/18/25 7:53:47 AM ET
      $MLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MoonLake Immunotherapeutics upgraded by Goldman with a new price target

      Goldman upgraded MoonLake Immunotherapeutics from Neutral to Buy and set a new price target of $82.00 from $62.00 previously

      1/17/25 7:44:04 AM ET
      $MLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MLTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Bvf Partners L P/Il

      4 - MoonLake Immunotherapeutics (0001821586) (Issuer)

      6/9/25 7:16:08 PM ET
      $MLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Sturge Simon

      4 - MoonLake Immunotherapeutics (0001821586) (Issuer)

      6/9/25 9:08:48 AM ET
      $MLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Loy Spike

      4 - MoonLake Immunotherapeutics (0001821586) (Issuer)

      6/9/25 9:07:53 AM ET
      $MLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MLTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update

      MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update Continued to make significant progress with the development of the Nanobody® sonelokimab across portfolio of indications, including Phase 3 studies in hidradenitis suppurativa (HS), psoriatic Arthritis (PsA) and adolescent HS, as well as Phase 2 studies in palmoplantar pustulosis (PPP) and axial spondyloarthritis (axSpA)Announced completion of enrollment of patients in the Phase 3 program in HS (the VELA program) and disclosed baseline characteristics, replicating the Phase 2 MIRA trialPresented an interim readout of the Phase 2 LEDA study in PPP, highlighting the potential of sonelokimab

      5/12/25 4:00:00 PM ET
      $HTGC
      $MLTX
      Investment Managers
      Finance
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29

      MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 Zug, Switzerland, April 25, 2025 – MoonLake Immunotherapeutics (NASDAQ:MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, will host a virtual Capital Markets Day for investors and analysts on Tuesday, April 29, 2025. The event will highlight recent financial and clinical milestones and provide future strategic updates. The webcast, streamed live from New York, will start at 8:30 AM EST (2:30 PM CET) and is expected to last one hour. A recording will be made available post event. Webcast Access: https://edge.media-server.com/mmc/p/sgz7i4x9 MoonLake'

      4/25/25 4:05:00 PM ET
      $MLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates

      Agreement with Hercules Capital significantly increases financial and operational strength, provides up to $500 million in capital with no dilution to shareholders, an attractive cost of capital and low operational and strategic incumbrances, and sets a new standard for the quantum of a nondilutive facility for a development-stage therapeutics company.Facility adds to the $448 million cash position disclosed in previously filed 10-K and provides funding for the next steps of the Company's growth, including the expected launch of sonelokimab in 2027, additional clinical trials and further investments for growth.The Company will hold an in-person and virtual Capital Markets Update on Tuesday,

      4/3/25 7:00:00 AM ET
      $HTGC
      $MLTX
      Investment Managers
      Finance
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MLTX
    SEC Filings

    See more
    • SEC Form 144 filed by MoonLake Immunotherapeutics

      144 - MoonLake Immunotherapeutics (0001821586) (Subject)

      7/3/25 1:23:21 PM ET
      $MLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MoonLake Immunotherapeutics filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - MoonLake Immunotherapeutics (0001821586) (Filer)

      6/6/25 4:30:13 PM ET
      $MLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by MoonLake Immunotherapeutics

      SCHEDULE 13G/A - MoonLake Immunotherapeutics (0001821586) (Subject)

      5/14/25 10:45:26 AM ET
      $MLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MLTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chen Bihua bought $3,524,297 worth of Class A Ordinary Shares (58,839 units at $59.90) (SEC Form 4)

      4 - MoonLake Immunotherapeutics (0001821586) (Issuer)

      10/10/23 4:00:43 PM ET
      $MLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chen Bihua bought $16,800,343 worth of Class A Ordinary Shares (293,212 units at $57.30) (SEC Form 4)

      4 - MoonLake Immunotherapeutics (0001821586) (Issuer)

      10/4/23 5:52:22 PM ET
      $MLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MLTX
    Financials

    Live finance-specific insights

    See more
    • MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update

      MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update Continued to make significant progress with the development of the Nanobody® sonelokimab across portfolio of indications, including Phase 3 studies in hidradenitis suppurativa (HS), psoriatic Arthritis (PsA) and adolescent HS, as well as Phase 2 studies in palmoplantar pustulosis (PPP) and axial spondyloarthritis (axSpA)Announced completion of enrollment of patients in the Phase 3 program in HS (the VELA program) and disclosed baseline characteristics, replicating the Phase 2 MIRA trialPresented an interim readout of the Phase 2 LEDA study in PPP, highlighting the potential of sonelokimab

      5/12/25 4:00:00 PM ET
      $HTGC
      $MLTX
      Investment Managers
      Finance
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update

      Initiated the Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS) and the Phase 3 IZAR program in patients with active psoriatic arthritis (PsA) following positive FDA and EMA regulatory feedback, continuing to support a potential best-in-class profile across two key indicationsInitiated three new trials in the beginning of 2025 with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent hidradenitis suppurativa (HS), Phase 2 LEDA trial in palmoplantar pustulosis (PPP) and Phase 2 S-OLARIS trial in axial spondyloarthritis (axSpA)Signed a three-year technology partnership with Komodo Health to advance research on inflam

      2/26/25 7:00:00 AM ET
      $MLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update

      MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update Ended the third quarter with $493.9 million in cash, cash equivalents and short-term marketable debt securities, expected to support a roadmap rich in potential catalysts and a cash runway to the end of 2026Strong market performance of other IL-17 inhibitors in hidradenitis suppurativa (HS) and other inflammatory indications validating large market opportunity for sonelokimabPhase 3 clinical program in HS is progressing as per plan with primary endpoint readout anticipated as of mid-2025Preparations for Phase 3 clinical program in psoriatic arthritis (PsA) completed with patient enrollmen

      11/7/24 7:00:00 AM ET
      $MLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MLTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by MoonLake Immunotherapeutics

      SC 13G/A - MoonLake Immunotherapeutics (0001821586) (Subject)

      11/12/24 10:32:13 AM ET
      $MLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by MoonLake Immunotherapeutics

      SC 13D/A - MoonLake Immunotherapeutics (0001821586) (Subject)

      10/8/24 6:48:48 PM ET
      $MLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by MoonLake Immunotherapeutics (Amendment)

      SC 13D/A - MoonLake Immunotherapeutics (0001821586) (Subject)

      3/5/24 4:59:16 PM ET
      $MLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care